Septerna (SEPN) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Septerna, Inc. ( SEPN ) UBS Global Biopharma Conference 2026 November 16, 2026 9:00 AM EST Company Participants Jeffrey Finer - Co-Founder, CEO & Director Liz Bhatt - President & COO Conference Call Participants Alice Ne…

Septerna, Inc. is positioned for near-term value creation, with SEP-479 as the primary catalyst and a strong cash runway into 2029. SEP-479's Phase 1 readout in 1Q27 could provide the first meaningful clinical validation…

Septerna, Inc. (SEPN) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.09 per share a year ago.…

Phase 1 Clinical Trial for PTH1R Agonist SEP-479 Ongoing; SAD / MAD Data Expected in Q1 2027 Plans to Initiate Phase 1 Clinical Trial of Newly Selected Oral TSHR NAM Development Candidate SEP-204 in Q1 2027 Cash Position…

Potent, selective TSHR NAM with pre-clinical activity demonstrated across biochemical, thyroid and ocular endpoints Favorable PK profile anticipated to support once-daily oral dosing in humans Phase 1 clinical trial init…

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announc…

Septerna, Inc. (NASDAQ: SEPN - Get Free Report) COO Elizabeth Bhatt sold 4,000 shares of the company's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $37.41, for a total …

Septerna (NASDAQ: SEPN - Get Free Report) and CRISPR Therapeutics (NASDAQ: CRSP - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of …

Valneva (NASDAQ: VALN - Get Free Report) and Septerna (NASDAQ: SEPN - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of t…

Septerna (NASDAQ: SEPN - Get Free Report) and WAVE Life Sciences (NASDAQ: WVE - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on…

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Septerna, Inc. (NASDAQ: SEPN) during a recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fu…

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), today announced that the Company granted a non-qualified stock option to purchase up to 275,000 shares of the Company's commo…

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announ…

Septerna, Inc. has surged >315% since May 2025, driven by its GPCR-focused drug discovery and a high-profile collaboration with Novo Nordisk. The SEPT partnership with NOVO targets GLP-1, GIP, and glucagon receptors, wit…

SOUTH SAN FRANCISCO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announc…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

